A detailed history of Janus Henderson Group PLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Janus Henderson Group PLC holds 1,042,795 shares of VRNA stock, worth $44.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,042,795
Previous 1,092,042 4.51%
Holding current value
$44.5 Million
Previous $15.8 Million 90.0%
% of portfolio
0.02%
Previous 0.01%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.46 - $30.16 $761,358 - $1.49 Million
-49,247 Reduced 4.51%
1,042,795 $30 Million
Q2 2024

Aug 14, 2024

SELL
$11.48 - $17.02 $10.8 Million - $16 Million
-939,952 Reduced 46.26%
1,092,042 $15.8 Million
Q1 2024

May 15, 2024

BUY
$15.3 - $20.24 $3.5 Million - $4.63 Million
228,633 Added 12.68%
2,031,994 $32.7 Million
Q4 2023

Feb 14, 2024

BUY
$11.94 - $20.47 $1.99 Million - $3.41 Million
166,539 Added 10.17%
1,803,361 $35.9 Million
Q3 2023

Nov 14, 2023

BUY
$16.3 - $22.09 $19.8 Million - $26.8 Million
1,212,266 Added 285.54%
1,636,822 $26.7 Million
Q2 2023

Aug 14, 2023

BUY
$19.41 - $23.43 $3.91 Million - $4.72 Million
201,527 Added 90.36%
424,556 $8.98 Million
Q1 2023

May 15, 2023

SELL
$18.06 - $25.27 $5.7 Million - $7.98 Million
-315,605 Reduced 58.59%
223,029 $4.48 Million
Q4 2022

Feb 14, 2023

BUY
$9.84 - $26.13 $2.35 Million - $6.24 Million
238,634 Added 79.54%
538,634 $14.1 Million
Q3 2022

Nov 14, 2022

BUY
$4.14 - $13.59 $1.24 Million - $4.08 Million
300,000 New
300,000 $3.07 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.6B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.